Who We Are
The VCTL is an academic cGMP laboratory with the aim of providing expert advice and cGMP and GLP services that help investigators, clinician scientists and small biopharmaceutical companies in initiating early phase clinical trials. Since becoming functional in 2015, the VCTL has produced personalized cancer vaccines, shared antigen cancer vaccines, stem cell infusion products, cell-based vaccines, Influenza vaccine seeds and most recently live virus vaccines against Covid-19.
Our Philosophy
The Vaccine and Cell Therapy Laboratory (VCTL) serves an important role in translating promising laboratory results into novel therapies by providing a dedicated and controlled facility for the manufacturing of immunotherapies and testing their effectiveness in vaccinated patients for phase I and II clinical trials in cancer and infectious diseases. This highly specialized facility is an essential component of the Tisch Cancer Institute’s Immunotherapy Program.
Our Mission
To advance translational research and development in the fields of immuno-therapeutics, cell therapies and neoantigen vaccines through collaborations with academic investigators and industry partners.